title: Anti-VEGF therapies in the clinic.
abstract: The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies.
authors.affiliation: Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: Kellen L
authors.initials: KL
authors.lastname: Meadows
authors.forename: Herbert I
authors.initials: HI
authors.lastname: Hurwitz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A